OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa
SUWON, South Korea, May 9, 2019 /PRNewswire/ -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics,announced today an expansion of its ocular disease pipeline. Specifically, the company announced that OLX304A has been added to develop an RNAi therapeutic with...
OliX Pharmaceuticals Announces The Ophthalmologist Demetrios G. Vavvas, M.D., Ph.D., to join Scientific Advisory Board
SUWON, South Korea, April 22, 2019 /PRNewswire/ -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has today announced that Demetrios G. Vavvas, M.D., Ph.D., one of the world leaders in the field of Ophthalmology, has joined its Scientific Advisory Board (SA...
Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD
- License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration. - OliX to receive an upfront payment of 2 million euro, and eligible to receive milestones, plus royalty for the development and commerci...
OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy
SUWON, South Korea, Jan. 18, 2019 /PRNewswire/ -- OLX10020, a cell-penetrating asymmetric siRNA ("cp-asiRNA") against a novel target (Undisclosed) for treatment of Geographic Atrophy ("GA"), proved effective in both Dry and Wet AMD animal models and to be submitted an IND application to the FDA ...
OliX, a RNAi therapeutics developer, gets approval for KOSDAQ listing
SUWON, South Korea, July 23, 2018 /PRNewswire/ -- OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, has successfully completed its public listing on the Korea Securities Dealer Automated Quotation (KOSDAQ) in the Korean stock market onJuly 18. On its first d...
